Kamada (NASDAQ:KMDA) Shares Pass Below 200 Day Moving Average - Here's What Happened

Key Points

• Kamada Ltd. shares have fallen below their 200-day moving average, closing at $6.97, signaling potential instability in the stock price.
• Wall Street analysts remain optimistic, with a consensus rating of "Moderate Buy" and an average price target of $13.00, despite the recent stock decline.
• The company reported a quarterly EPS of $0.13, exceeding expectations, yet its revenue was significantly below the consensus estimate, indicating mixed financial performance.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $7.03 and traded as low as $6.92. Kamada shares last traded at $6.97, with a volume of 34,115 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on KMDA shares. Benchmark reaffirmed a "buy" rating and set a $15.00 price objective on shares of Kamada in a report on Thursday, May 15th. Wall Street Zen upgraded shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Finally, Sidoti upgraded shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Kamada Trading Down 0.7%

The firm has a market capitalization of $400.84 million, a price-to-earnings ratio of 20.50, a PEG ratio of 0.73 and a beta of 0.89. The business's fifty day moving average price is $7.42 and its 200 day moving average price is $7.03.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.04. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kamada

Several hedge funds have recently modified their holdings of KMDA. JPMorgan Chase & Co. purchased a new position in Kamada in the fourth quarter valued at approximately $67,000. Trexquant Investment LP acquired a new position in shares of Kamada during the first quarter valued at $82,000. Cubist Systematic Strategies LLC bought a new stake in shares of Kamada during the first quarter valued at about $206,000. Jump Financial LLC bought a new stake in shares of Kamada during the second quarter valued at about $219,000. Finally, NewEdge Advisors LLC raised its position in Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock worth $341,000 after acquiring an additional 28,165 shares in the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.